Drug Companies Block Shareholder Votes on Price Transparency Proposals: Investors’ group wants companies to disclose price increases over the years, and the rationale
This article is behind a paywall. Harvard affiliates can access it via Hollis+.
Several major U.S. drug companies have squelched an investor campaign aimed at forcing companies to disclose more information about when and why they raise prices. [...]health care finance pharmaceuticals regulation